What is the appropriate diagnostic work‑up and management for an epithelioid and spindled thoracic neoplasm suspected to be sarcomatoid carcinoma, malignant mesothelioma, sarcoma, or metastatic disease?

Diagnostic Work-Up and Management of Epithelioid and Spindled Thoracic Neoplasm

Proceed immediately to thoracoscopic pleural biopsy to obtain tissue for definitive histologic diagnosis and comprehensive immunohistochemical profiling, as cytology and imaging alone cannot reliably distinguish between sarcomatoid carcinoma, malignant mesothelioma, sarcoma, or metastatic disease. 1

Initial Diagnostic Strategy

Tissue Acquisition is Mandatory

• Thoracoscopic biopsy (medical or surgical) is the gold standard, achieving >92-95% diagnostic sensitivity and providing sufficient tissue for immunohistochemistry, molecular profiling, and assessment of tissue invasion 1
• The procedure allows multiple biopsies from different pleural sites and direct visualization of tumor distribution 1
• CT-guided core needle biopsy is an acceptable alternative when thoracoscopy is contraindicated, but blind pleural biopsies should never be performed 1
• Place specimens in both saline (for microbiology) and formalin (for histopathology) 1

Why Tissue Biopsy Cannot Be Bypassed

• Recognition of tissue invasion is mandatory for diagnosing malignant mesothelioma and cannot be assessed on cytology alone 1
• Cytology has extreme difficulty differentiating malignant mesothelioma cells from reactive benign mesothelial cells 1
• Adequate tissue permits gene-expression profiling and receptor-status testing for targeted therapies 1
• The International Mesothelioma Interest Group mandates that mesothelioma diagnosis must always be based on tissue biopsy, never cytology alone 1

Comprehensive Immunohistochemical Panel

For Sarcomatoid/Spindle Cell Morphology

First, establish epithelial differentiation:

• Cytokeratin stains (AE1/AE3, CAM5.2, MNF-116) are essential to distinguish sarcomatoid carcinoma and sarcomatoid mesothelioma from true sarcomas 2, 3
• Cytokeratin positivity in spindle cell lesions excludes pure sarcoma but does not distinguish sarcomatoid mesothelioma from sarcomatoid carcinoma 3, 4

Second, apply mesothelial markers:

• D2-40 (podoplanin) shows 100% sensitivity for sarcomatoid mesothelioma and is the most reliable marker 2
• Calretinin is positive in only 25% of sarcomatoid mesotheliomas (versus 80% in epithelioid type), limiting its utility 2
• WT-1 nuclear staining is positive in only 33% of sarcomatoid mesotheliomas 2

Third, apply carcinoma-specific markers:

• TTF-1 and napsin A are positive in lung adenocarcinoma and negative in mesothelioma 5
• CEA, BerEP4, MOC-31, and Claudin-4 are positive in adenocarcinomas and negative in mesotheliomas 5

For Epithelioid Morphology

• Positive mesothelial markers: calretinin, CK5/6, WT-1, podoplanin 5
• Negative carcinoma markers: CEA, EPCAM (MOC-31, BerEP4), blood group 8, Claudin 4 5
• TTF-1 and napsin A to exclude lung primary 5

Molecular Markers for Mesothelioma Confirmation

• FISH for homozygous p16/CDKN2A deletion at 9p21 supports mesothelioma over benign reactive process 5, 1
• Loss of BAP1 expression by immunohistochemistry is highly specific for malignant mesothelioma (though negative results do not exclude disease) 5, 1

Staging and Metastatic Work-Up

Imaging Protocol

• Chest CT with contrast is mandatory for all patients to assess extent of pleural disease and detect pulmonary metastases 5
• MRI is preferred for chest wall invasion assessment in extremity or superficial trunk lesions if sarcoma is suspected 5
• Abdominal/pelvic CT should be obtained for leiomyosarcoma, epithelioid sarcoma, or angiosarcoma due to higher metastatic risk to these sites 5
• Brain MRI is indicated for alveolar soft part sarcoma and angiosarcoma due to propensity for CNS metastases 5

Additional Diagnostic Studies

• PET/CT may be useful for prognostication and grading in sarcoma, and to assess chemotherapy response 5
• Flow cytometry on pleural fluid (if present) offers 50-94% sensitivity for non-lymphoma malignancies when lymphoma is in the differential 1

Histologic Subtype Documentation and Prognostic Implications

Mesothelioma Subtyping is Mandatory

• Document whether epithelioid, sarcomatoid, or biphasic, as this has critical prognostic and therapeutic implications 5
• Median survival for epithelioid, biphasic, and sarcomatoid mesothelioma is 19,12, and 4 months respectively 5
• Surgery is not recommended for sarcomatoid mesothelioma as these patients fail to benefit and have much shorter survival 5
• In biphasic mesothelioma, quantify the percentage of epithelioid versus sarcomatoid components, as >50% epithelioid differentiation predicts better survival (11.8 vs 6.6 months) 5

Sarcoma Grading and Subtyping

• Document histologic grade (low versus high) as this determines adjuvant therapy recommendations 5
• Identify specific sarcoma subtype (e.g., leiomyosarcoma, angiosarcoma, synovial sarcoma) as some have distinct metastatic patterns and treatment approaches 5

Differential Diagnosis Algorithm

When cytokeratin-positive spindle cells are present:

1. If D2-40/podoplanin positive + mesothelial markers positive + carcinoma markers negative + diffuse pleural involvement → Sarcomatoid mesothelioma 2, 6
2. If TTF-1 positive or other carcinoma markers positive → Sarcomatoid carcinoma (lung primary or metastatic) 6, 4
3. If both mesothelial and epithelial markers are equivocal, correlate with clinical/imaging findings: diffuse pleural thickening favors mesothelioma; discrete lung mass favors sarcomatoid carcinoma 6, 4

When cytokeratin-negative spindle cells are present:

• Consider primary sarcoma (fibrosarcoma, malignant peripheral nerve sheath tumor, etc.) 3, 7
• Apply sarcoma-specific markers (desmin for rhabdomyosarcoma, S100 for nerve sheath tumors, CD34 for solitary fibrous tumor) 3, 7

Critical Pitfalls to Avoid

• Do not diagnose mesothelioma on cytology alone; atypical mesothelial cells in pleural fluid are diagnostically indeterminate and require tissue confirmation 1
• Do not delay biopsy for repeat cytology; if initial fluid shows atypical cells and clinical suspicion is high, proceed directly to tissue sampling 1
• Do not rely solely on calretinin and WT-1 for sarcomatoid mesothelioma, as these are positive in only 25-33% of cases; use D2-40/podoplanin instead 2
• Clinical and radiologic correlation is essential when immunohistochemistry shows overlapping features, as poorly differentiated tumors may not express typical markers 6, 4
• Up to 15% of patients with initial nonspecific pleuritis are later diagnosed with pleural malignancy (most often mesothelioma); implement long-term radiological monitoring if suspicion remains high 1

Management Based on Final Diagnosis

If Sarcomatoid Mesothelioma

• Surgery is not recommended due to lack of survival benefit 5
• Systemic chemotherapy is the primary treatment, though response rates are lower than epithelioid subtype 5

If Sarcomatoid Carcinoma

• Identify primary site through organ-specific markers (TTF-1 for lung, mammaglobin/ER/PR for breast, CDX-2 for GI) 1
• Treat according to primary tumor protocols 1

If Sarcoma

• Wide surgical excision with R0 margins (>1 cm) is the primary treatment for localized disease 5
• Postoperative radiation therapy is recommended for high-grade, deep lesions >5 cm (50-60 Gy) 5
• Consider preoperative chemotherapy for large high-grade tumors (>8-10 cm) at high risk for metastases 5